IMM 1.49% 34.0¢ immutep limited

While the data looks promising, it is early to speculate on...

  1. 45 Posts.
    lightbulb Created with Sketch. 3
    While the data looks promising, it is early to speculate on commercialization due to patients having side-effects such as breathing difficulties. There is a scope for further optimizing the treatment strategy which can take one step closure to commercialization.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.